GEXVal Selected as Presenting Company at BioEquity Europe 2026

株式会社GEXVal
May 7, 2026

GEXVal CEO Selected to Present at BioEquity Europe 2026

GEXVal Inc. (President & CEO: Juran Kato, PhD; Fujisawa, Kanagawa, Japan; hereinafter “GEXVal”) today announced that it has been selected as a presenting company at BioEquity Europe 2026, one of Europe's leading international biotech investment conferences hosted by BioCentury and EBD Group, and Dr. Kato presented at the event held in Prague, Czech Republic.

[Event Overview]
BioEquity Europe is a premier international investment conferences in the biotechnology and pharmaceutical sector, bringing together institutional investors, venture capital firms, and business development executives from leading pharmaceutical companies worldwide. The 2026 edition marked the conference’s 26th annual gathering, held at the Prague Congress Centre in Prague, Czech Republic. This marked GEXVal’s second selection as a presenting company, following its selection in 2025, with Dr. Kato presenting on this occasion.

**Presentation Details**

[CEO Comment]
It was a great pleasure to have the opportunity to share GXV-001's clinical value and our vision directly with investors from Europe and around the world at BioEquity Europe 2026. GXV-001 is a clinical-stage asset that continues to advance steadily, having completed Phase 1 and received FDA Orphan Drug Designation with the support of patient advocacy groups. We remain committed to addressing the significant unmet needs in neurological disorders — including Fragile X Syndrome ¹⁾ as well as the delirium/dementia continuum, and will continue our preparations toward Phase 2a.

1) About Fragile X syndrome (FXS): Fragile X syndrome is a rare, congenital disorder caused by mutations in the FMR1 gene on the X chromosome, resulting in loss of FMRP protein function. In Japan, FXS is designated as Specified Intractable Disease No. 206* and is classified as a developmental disorder. FXS is classified within the autism spectrum, and its main characteristics include autistic-like behaviors, attention difficulties and hyperactivity, anxiety, sensory sensitivities, epilepsy, sleep disturbances, and intellectual disability. According to FRAXA Research Foundation, FXS is considered the most common known genetic cause of autism and intellectual disabilities. Currently, there are no approved treatments for FXS, representing a significant unmet medical need for patients and their families.

*: Japan's Specified Intractable Disease designation is granted under the Act on Medical Care for Patients with Intractable Diseases (enforced January 2015), which built on a national rare-disease policy framework dating back to 1972. To qualify, a disease must have an unknown cause, no established treatment, require long-term care, and affect no more than approximately 0.1% of Japan's population, among other criteria. As of April 2026, 348 diseases were designated. Designated patients are eligible for subsidized medical costs, including a monthly out-of-pocket cap based on income.

For more information (Japanese only), see the Japan Intractable Disease Information Center: https://www.nanbyou.or.jp/entry/4141

Additional Resources:

• Japan Intractable Disease Information Center: https://www.nanbyou.or.jp/entry/4612
• National Organization for Rare Disorders (NORD): https://rarediseases.org/rare-diseases/fragile-x-syndrome/
• Orphanet: https://www.orpha.net/en/disease/detail/908?name=fxs&mode=name
• FRAXA Research Foundation: https://www.fraxa.org

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有关本事宜请咨询:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com